Drug Discovery World

JANUARY 10, 2023

For over 50 years, Bethyl Laboratories (now a Fortis Life Sciences brand) has been dedicated to improving lives by supporting scientific discovery through qualified antibody products and custom services. Antibody validation. Antibody validation. A proposal for validation of antibodies.

Antibody 52

Antibody Protein Reagent Scientist 52

Drug Discovery World

MAY 25, 2023

Several new products for the life sciences sector have been launched over the last month, from miniature semiconductor chip (MSC) technology to a new inhalation testing service. The platform works with the SYNTAX Hi-Fidelity reagent kits for synthesising longer oligos. DDW provides an update.

Production 52

Production Reagent DNA Drugs 52

Drug Discovery World

APRIL 3, 2023

I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development. What advantages do they offer over antibodies?   DS: How are aptamers currently used in the development of precision treatments?

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

Drug Discovery World

DECEMBER 13, 2023

This article is sponsored by Fortis Life Sciences. In the ever-evolving landscape of therapeutic development, the role of antibodies has become increasingly apparent. Antibodies are used as therapeutics, components of therapeutics such as antibody-drug conjugates (ADC) and CAR-T cells, and as companion diagnostic tools.

Life Science 59

Life Science Antibody Manufacturing In-Vivo 59

Drug Discovery World

OCTOBER 13, 2022

The DDW team spent 4-5 October, 2022 at ELRIG’s annual meeting, Drug Discovery 2022, which remains Europe’s largest meeting for life sciences industry professionals and took place at ExCel, London, UK. Looking forward .

Drugs 52

Drugs In-Vivo In-Vitro Biobanking 52

Drug Discovery World

NOVEMBER 30, 2023

The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows. This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It GSK has developed high-throughput mammalian and E.

Antibody 59

Antibody Protein Engineer In-Vivo 59

XTalks

APRIL 22, 2022

Generally, antibody-based therapeutics are one of the main types of drugs that are assessed using receptor occupancy assays as they bind to specific cell surface receptors through which they impact downstream intracellular signalling pathways. The antibodies are conjugated to fluorochromes for them to be detected.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98